BM-230 / Suzhou Biomissile Pharmaceuticals - LARVOL DELTA

A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=90 | Not yet recruiting | Sponsor: Suzhou Biomissile Pharmaceuticals Co., Ltd.

New P1/2 trial • Esophageal Squamous Cell Carcinoma • Oncology • Solid Tumor

11 Class 1 innovative drugs were approved for clinical trials in China for the first time! From Sanofi, Hengrui Medicine and other companies [Google translation] (Sina Corp) - "The Class 1 new drug S095029 applied by Servier has been approved for clinical trials and is intended to be developed to treat locally advanced unresectable or metastatic MSI-H/dMMR gastroesophageal junction cancer/gastric cancer...The lyophilized preparation of BM230, a Class 1 new drug applied by Biomins, has been approved for clinical trials and is intended to be developed to treat HER2-related solid tumors...Hengrui Medicine 's Class 1 new drug SHR-4375 injection has been approved for clinical trials and is intended to be developed to treat solid tumors....The Class 1 new drug SCG142 autologous T cell injection submitted by Xinghand Bio has been approved for clinical trials and is intended to be developed to treat HPV16 or HPV52-related malignancies."

New trial • Cervical Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Head and Neck Cancer • Microsatellite Instability • Oral Cancer • Penile Cancer • Solid Tumor • Vulvar Cancer • HER-2

Study of BM230 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=123 | Recruiting | Sponsor: Suzhou Biomissile Pharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor